Logo Image
Feature|Videos|September 26, 2025

An End-to-End Enabler of Biologic Innovation

David McErlane, Group President of Biologics at Catalent, shares how integrated expertise in biologics helps simplify complexity, accelerate development, and deliver therapies to patients faster.

In an increasingly complex industry, Catalent supports biopharma partners by simplifying the inherent intricacies of biologics development. With integrated capabilities spanning drug substance, drug product, and bioanalytics along with deep scientific, regulatory, and operational expertise, Catalent helps customers anticipate challenges and deliver life-changing therapies to patients. In this interview, David McErlane, Group President of Biologics at Catalent, shares his insights on current industry challenges, as well as delivering value beyond technical capabilities.

Learning Objectives:

  • Learn how integrated services across the biologics value chain can reduce complexity and risk for biopharma companies.
  • Understand the importance of early collaboration, scale-up strategy, and regulatory expertise in accelerating biologics development.
  • Explore how Catalent’s scientific depth and operational excellence enable faster problem-solving and greater confidence in advancing therapies to patients.

Related to this article

View more
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Read more
The Promise of Microgravity for R&D and Manufacturing
The Promise of Microgravity for R&D and Manufacturing
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Read more